Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways.
Cancer Lett
; 326(2): 135-42, 2012 Dec 30.
Article
en En
| MEDLINE
| ID: mdl-22863538
ABSTRACT
In this study, we investigated the synergistic effects of panobinostat and bortezomib on adriamycin-resistant HL60/ADR cells and refractory acute myelogenous leukemia (AML) primary cells. Combination of both agents had synergistic cytotoxicity on these cells, and increased the sensitivity of HL60/ADR cells to adriamycin. Panobinostat plus bortezomib was shown to modulate multiple apoptotic and drug metabolic related molecules, including activation of caspases, down-regulation of XIAP, Bcl-2 and MRP1. These effects were likely to be mediated via inhibition of AKT and NF-κB pathways. These findings provide evidence for clinic protocols using panobinostat and borezomib to overcome drug resistance in refractory AML patients.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Pirazinas
/
Ácidos Borónicos
/
Leucemia Mieloide Aguda
/
FN-kappa B
/
Proteínas Proto-Oncogénicas c-akt
/
Ácidos Hidroxámicos
/
Indoles
/
Antineoplásicos
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
Cancer Lett
Año:
2012
Tipo del documento:
Article
País de afiliación:
China